Scarica l'app Stockscreener
4.25
3.16%
0.13
Dopo l'orario di chiusura:
4.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SGHT Giù?
Forum
Previsione
Precedente Chiudi:
$4.12
Aprire:
$4.15
Volume 24 ore:
160.59K
Relative Volume:
1.01
Capitalizzazione di mercato:
$219.71M
Reddito:
$81.06M
Utile/perdita netta:
$-55.55M
Rapporto P/E:
-3.7281
EPS:
-1.14
Flusso di cassa netto:
$-47.98M
1 W Prestazione:
+21.78%
1M Prestazione:
+24.63%
6M Prestazione:
+66.02%
1 anno Prestazione:
-26.60%
Intervallo 1D:
$4.10
$4.28
Intervallo di 1 settimana:
$3.41
$4.28
Portata 52W:
$2.03
$7.05
Sight Sciences Inc Stock (SGHT) Company Profile
Nome
Sight Sciences Inc
Settore
Industria
Telefono
(415) 889-0550
Indirizzo
4040 CAMPBELL AVE,, MENLO PARK
Confronta SGHT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
4.25 | 219.22M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
131.02 | 233.71B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.64 | 152.83B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
376.61 | 144.35B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.08 | 119.00B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.93 | 46.00B | 5.69B | 4.14B | 577.90M | 6.96 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-08 | Aggiornamento | Lake Street | Hold → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-11-04 | Downgrade | Lake Street | Buy → Hold |
| 2024-08-21 | Iniziato | Lake Street | Buy |
| 2023-09-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-09-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-08-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-04 | Iniziato | Needham | Hold |
| 2022-07-26 | Iniziato | Stifel | Hold |
| 2022-02-03 | Iniziato | William Blair | Outperform |
| 2022-01-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Sight Sciences Inc Borsa (SGHT) Ultime notizie
Will Sight Sciences Inc. see short term momentumSafe Investment Ideas with Growth Upside - Newser
Is Sight Sciences Inc. Stock a Good Fit for Conservative InvestorsEntry Optimization Guide with Volume Analysis - Newser
Analyzing Sight Sciences Inc. with risk reward ratio chartsFree Community Shared Smart Money Signals - Newser
Will Sight Sciences Inc. price bounce be sustainableFree AI Driven Buy Alert Trade Blueprint - Newser
Sight Sciences, Inc. (NASDAQ:SGHT) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛
Sight Sciences (NASDAQ:SGHT) Raised to Hold at Wall Street Zen - Defense World
Will earnings trigger a reversal in Sight Sciences Inc.Free Conservative Long Term Growth Plans - Newser
Chart based exit strategy for Sight Sciences Inc.Free Price Action Based Buy Opportunity List - Newser
Real time breakdown of Sight Sciences Inc. stock performanceFree Intraday Trend Analysis for Fast Gains - Newser
Risk adjusted return profile for Sight Sciences Inc. analyzedPrice Action Trading with Volume Confirmation - Newser
Sight Sciences, Inc. (NASDAQ:SGHT) Q2 2025 Earnings Call Transcript - MSN
Sector Leaders Rotate Capital Into Sight Sciences Inc.Community Shared Smart Money Signals Show Movement - metal.it
Sight Sciences raises 2025 revenue guidance to $72M–$76M amid strong OMNI growth and strategic focus on MIGS leadership - MSN
Compared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key Metrics - MSN
Does Sight Sciences (NASDAQ:SGHT) Have A Healthy Balance Sheet? - simplywall.st
A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $4 to $5 - 富途牛牛
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Sight Sciences Reports Q2 EPS, Revenue Above Consensus, Glaucoma Ordering Accounts Reach New High - AInvest
Sight Sciences stock rating upgraded by Lake Street on stabilizing business - Investing.com Australia
Sight Sciences shares surge 17.75% intraday after strong Q2 earnings and upgraded rating by Lake Street analyst. - AInvest
Sight Sciences' Q2 2025: Navigating Contradictions in TearCare Reimbursement and Market Dynamics - AInvest
Sight Sciences Boosts 2025 Revenue Guidance to $72M-$76M on OMNI Growth and MIGS Leadership Focus - AInvest
Earnings call transcript: Sight Sciences Q2 2025 beats revenue expectations By Investing.com - Investing.com Nigeria
Earnings call transcript: Sight Sciences Q2 2025 beats revenue expectations - Investing.com
Sight Sciences August 2025 slides: Targeting growth in $9B eye care market despite Q1 headwinds - Investing.com Australia
Sight Sciences 2025 Q2 Earnings Slight Improvement in Losses Amid Revenue Decline - AInvest
Sight Sciences Reports Q2 2025 Financial Results - TipRanks
Sight Sciences Lifts Outlook Despite Revenue Slump - Finimize
Sight Sciences Releases Second Quarter Results and Raises Full-Year Guidance - VisionMonday.com
Sight Sciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Sight Sciences, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Sight Sciences reports Q2 EPS (23c), consensus (28c) - TipRanks
Sight Sciences: Navigating Revenue Headwinds and Regulatory Challenges to Secure Long-Term Growth - AInvest
Sight Sciences: A Resilient Earnings Beat Signals Undervaluation and Growth in Ophthalmic Innovation - AInvest
Sight Sciences Raises Full-Year Revenue Guidance - TipRanks
Sight Sciences earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - GlobeNewswire
SAHARA trial demonstrates sustained TearCare benefits for evaporative DED - Ophthalmology Times
Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye - Optometry Times
Strategies to average down on Sight Sciences Inc.Day Trading Setup Forecast with Trend Model - Newser
Sight Sciences (SGHT) to Release Quarterly Earnings on Thursday - Defense World
What high frequency data says about Sight Sciences Inc.Equity Signal Recap With Long-Term Summary - Newser
What makes Sight Sciences Inc. stock price move sharplyFree Fundamental Growth Stock Analysis - Newser
Will Sight Sciences Inc. outperform the marketFree Community Verified Stock Suggestions - Newser
Is Sight Sciences Inc. a good long term investmentInvest smarter with expert stock recommendations - Jammu Links News
Sight Sciences Inc Azioni (SGHT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sight Sciences Inc Azioni (SGHT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HAYDEN JEREMY B. | Chief Legal Officer |
Jul 03 '25 |
Sale |
4.17 |
9,160 |
38,234 |
266,321 |
| Bauerlein Alison | Chief Financial Officer |
Jul 02 '25 |
Sale |
4.10 |
19,260 |
78,927 |
617,468 |
| Badawi Paul | President and CEO |
Jul 01 '25 |
Sale |
4.15 |
23,637 |
98,141 |
5,986,943 |
| Badawi David | Chief Technology Officer |
Jul 03 '25 |
Sale |
4.17 |
5,679 |
23,704 |
1,831,025 |
| Link Matthew | Chief Commercial Officer |
Jul 02 '25 |
Sale |
4.10 |
4,889 |
20,035 |
832,293 |
1.57%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):